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Largest-Ever NCI Trial to Study Lung Cancer Screening
(Continued from page 1)
who have been randomly assigned to
undergo lung cancer screening with
either spiral CT or chest x-ray. The
participants will be screened at baseline
and then once a year for two years.
After the third screening test, they will
be followed up with phone and mail
surveys for another five to seven years.
“During the design of the trial,
many of us argued that the control
group should not receive an x-ray. But
the reality is that many people are doing
chest x-rays to screen, even though it’s
not recommended, so there was a desire
for the study to reflect current practice
and a concern that many people would
drop out of the trial if they didn’t get
an x-ray,” said Dr. Munden, who is the
principal investigator of the NLST
at M. D. Anderson.
Participants in the NLST will be
screened for free, but any additional tests
made necessary by the screening results
must be paid for by the participants or
their insurance providers. This is an
important consideration because spiral
CT, although extremely sensitive, lacks
specificity and yields a high rate of falsepositive results. A lung abnormality
found by spiral CT screening requires
follow-up testing, which can include a
diagnostic CT, positron emission tomography, a lung biopsy, or even surgery.
“So the biggest problem with screening
with CT is that we find a lot of abnormalities that aren’t significant; however,
we don’t know that until we spend more
money and do more tests, which can be
expensive,” Dr. Munden said.
The mental anguish that patients
must go through while waiting for a
diagnosis after having an abnormal
result on a screening CT is another
consideration. Most important, however, are the physical risks that accompany lung biopsy and surgery. Lung
biopsy can result in serious complications, including bleeding, infection,
and the partial collapse of a lung.
“So screening is not without risks.
Everyone has the perception that the
results are either negative or positive,
but it is not that crystal clear,” said Dr.
Munden. “The results that are truly
negative and the ones that are almost
certainly cancer, those are easy. But
2

OncoLog • June 2003

everything that is in between—perhaps
in as many as 70% of our participants—
those are the ones you have to deal with,
and it can be complicated.”
In fact, an important component in
the development of the NLST was an
attempt to address the difficulties
inherent in reading screening CT scans
of the lungs. The American College of
Radiology Imaging Network (ACRIN)
submitted a proposal to the NCI for a
lung cancer screening trial that included
a focus on the technical aspects of CT
screening and the interpretation of CT
scans. At about the same time, another
group, the network conducting the
Prostate, Lung, Colorectal, and Ovarian
Cancer Screening Trial, submitted a
separate lung cancer screening proposal
to the NCI, which merged the two
proposals into one large, comprehensive
trial, the NLST.
The ACRIN study sites, which
include M. D. Anderson, are conducting additional tests to measure quality
of life, smoking cessation, and smoking
addiction. Also, M. D. Anderson is
one of 10 sites at which researchers
are asking participants to allow them
to collect samples of blood, urine, and
sputum for use in future studies of lung
cancer biomarkers.
“The hope is that in the people in
whom we find lung cancer, we can go
back and look at their samples to see
if there is something different in their
genetic markers from the other group,”
said Dr. Munden. Identifying genetic
changes that place people at higher risk
for lung cancer could help researchers
decide who should be screened for
lung cancer and at what age.
When the NLST opened in September 2002, centers were given two
years to enroll participants. Recently,
however, in an effort to obtain results as
quickly as possible, the NCI shortened
the recruitment deadline to one year,
which has left many centers scrambling
to meet their recruitment goals.
To help spread the word about the
NLST, the NCI has teamed up with
the American Cancer Society (ACS),
which has donated money and other
resources to recruit participants for
the NLST.

Dr. Therese Bevers, an assistant
professor in the Department of Clinical
Cancer Prevention, is co-principal investigator of the NLST at M. D. Anderson.
“I think it’s a very exciting collaboration,” said Therese Bevers, M.D., an
assistant professor in the Department
of Clinical Cancer Prevention and coprincipal investigator in the NLST.
According to Dr. Bevers, the partnership with the ACS opens doors that
allow her to reach many more people
than would be possible otherwise. “It is
the first time that there has been a
collaboration between the ACS and
a large-scale prevention trial to recruit
participants. And what I think is so
wonderful about that is the ACS has
a fabulous grassroots network in the
community and a way of filtering and
getting that information out to the
people that I wouldn’t have, that the
NCI wouldn’t have,” she said.
The ACS is distributing information
about the NLST through fundraising
events such as the Relay For Life and
through its corporate connections. ●
FOR MORE INFORMATION, contact Dr.
Munden at (713) 792-5885 or Dr. Bevers
at (713) 745-8048. Those interested in
participating in the NLST may call (866)
295-3386 (toll free) or (713) 792-5340.
The American Cancer Society offers a
free counseling service called Quitline to
people who are trying to stop smoking.
The Quitline toll-free number is
(877) YES-QUIT ([877] 937-7848).

“What Choices Do I Have?”
Breast Reconstruction Book and CD-ROM
Help Patients Make Complicated Decisions
by Sunni Hosemann
and Kate Ó Súilleabháin

A

woman diagnosed
with breast cancer
today has a far
better chance of
being cured than her grandmother or even her mother had.
Still, in most cases, having
breast cancer means undergoing
surgery, and surgery leaves
scars, both physical and psychological. Restoring the missing
form of a woman’s breast after
mastectomy can be an important step in her recovery, often
signaling the end of the cancer
treatment and the return to a
normal life.
The many treatment and reconstructive options available to women today
can make decisions about breast
reconstruction surgery complicated,

however. Should the patient choose a
breast implant or an autologous tissue
transplant? If she opts for autologous
reconstruction, what type of tissue flap
should be used?
To educate patients about their
options for breast reconstruction, the
Department of Plastic Surgery at The
University of Texas M. D. Anderson
Cancer Center recently released two
resources: a CD-ROM and a full-length
book. Both the CD-ROM and the book
provide complete information in useful
formats that patients can explore on
their own time, guiding women through
the maze of information that is vital for
making the important choices about
breast reconstruction.
Informing patients fully of their
breast reconstruction options is challenging, in part because the consultation with the plastic surgeon usually
takes place when the patient is already
overwhelmed with information about
her cancer treatment.
“There is a lot of material to cover
in a short period of time,” said Gregory
P. Reece, M.D., a professor in the
Department of Plastic Surgery at M. D.
Anderson and editor of the book

“For many women, reconstruction is part of recovery from breast cancer,” said Dr.
Michael J. Miller, a professor in the Department of Plastic Surgery. Here, Dr. Miller
looks at the CD-ROM program Breast Reconstruction: What You Need to Know.

The Well-Informed Patient’s Guide to
Breast Reconstruction.
Breast reconstruction is secondary
to eradicating the cancer but should not
be considered an afterthought. In fact,
decisions about breast reconstruction
should be made early, as a woman’s
preferences about reconstruction can
influence her treatment choices and
vice versa. Some breast tumors, for
example, may be treated with a partial
mastectomy (lumpectomy) followed by
radiation therapy rather than by simple
mastectomy. Without having considered
reconstruction, many women would
choose to undergo the less extensive
lumpectomy, but depending on the size
of the breast, the size of the tumor, and
the woman’s preferred outcome, mastectomy might be the better choice to
ensure the best aesthetic results.
The timing of reconstructive surgery
can affect the results of breast reconstruction. Many women can undergo immediate reconstruction, which is performed
at the same time as the mastectomy. This
approach allows the plastic surgeon to
work with the general surgeon to perform
a skin-sparing mastectomy that can
enhance the appearance of the reconstructed breast. But aesthetics are not the
only consideration. Many women wish to
wake up after mastectomy with their new
breast already reconstructed, whereas
others choose to separate the cancer
treatment and the reconstruction process.
The CD-ROM program, Breast
Reconstruction: What You Need to Know,
was spearheaded by Michael J. Miller,
M.D., a professor in the Department of
Plastic Surgery, and produced by UT
Television. The program contains video
and animated illustrations, as well as a
feature that allows the user to print text
transcripts. Physicians and other healthcare professionals from the Department
of Plastic Surgery and the Nellie B.
Connally Breast Center at M. D.
Anderson deliver medical information,
but the program also features women
(Continued on page 4)
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The new 85,000-square-foot Proton Therapy Center at M. D. Anderson, which will open in 2006, will include four treatment
rooms, dedicated research space, a clinic, office space, and treatment-planning stations.

New Proton Therapy Center to Deliver
Radiation with Precision, Few Side Effects
by Kerry L. Wright
and Dawn Chalaire

C

onstruction of a
much-anticipated
85,000-square-foot
Proton Therapy
Center at The University of
Texas M. D. Anderson Cancer
Center officially began on
May 7 as representatives from
M. D. Anderson and private
investors attended a groundbreaking ceremony for the new
facility, which will take three
years and approximately $125
million to build. When it is
completed, the center will join
two existing hospital-based
proton therapy centers operating
in the United States and be the
largest of its kind in the world.
The advantage of proton therapy over
traditional radiation treatments is that it
is more precise in its delivery of radiation
dose to the targeted tumor, avoiding
many of the surrounding tissues, causing
fewer side effects, improving tumor
control, and increasing survival rates,
said James D. Cox, M.D., professor and
head of the Division of Radiation
Oncology at M. D. Anderson.
6
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The photons or electrons used in
conventional radiation therapy deposit
most of their energy in the tissues they
pass through before reaching the tumor
and often deliver radiation beyond the
targeted tumor to surrounding normal,
healthy tissue. Although advanced
techniques such as intensity-modulated
radiation therapy can reduce the exposure of healthy tissue to radiation, with
photon radiation therapy, the delivery of
at least a small amount of radiation to
these structures cannot be avoided.
“So we are often limited in the
radiation dose we can give to the tumor
because we are limited by the radiation
tolerance of the normal tissue surrounding the tumor,” said Dr. Cox.
Protons, in contrast, work in an
essentially reverse manner, entering
the body at a low dose that increases
when the beam, directed by a radiation
oncologist, nears its target, said Dr. Cox.
The largest dose is then deposited in the
tumor site, and the proton beams stop
there rather than continuing through
the body. “Protons kill cancer cells very
much like x-rays, but they can be aimed
with such precision as to concentrate
the cancer-killing effects only within
the tumor,” Dr. Cox said. “We will
be able to focus energy like we never
have before.”
Protons are energized to specific
velocities, and these energies determine
how deeply in the body the protons
will deposit their maximum energy.
Since proton beams are heavier than

their conventional counterparts, they
can be delivered more precisely and
prescribed to cover the entire tumor.
The result: proton beams can treat
tumors deep within the body while
producing minimal or no side effects
in surrounding tissues.
“So now, instead of asking what
the normal tissue tolerance is when
you irradiate a tumor, proton therapy
allows you to ask what amount of
harmful radiation is actually needed to
destroy the tumor,” said Mitch Latinkic,
division administrator for the Division
of Radiation Oncology. Latinkic came
to M. D. Anderson after participating in
the establishment of the first hospitalbased proton therapy center in the
United States at Loma Linda University
Medical Center in California, which
treated its first patient in 1990.
M. D. Anderson is aiming to open
its center in the early part of 2006. The
new facility will house four treatment
rooms, three of which will be equipped
with rotating gantries 35 feet in diameter
and weighing almost 200 tons each that
are capable of directing proton beams
with submillimeter precision. One of
these rooms will be designed to deliver
intensity-modulated proton therapy,
what Dr. Cox referred to as “the ultimate” in proton beam shaping. “There is
nothing that we can envision that is
going to be more precise,” he said.
The fourth treatment room will house
two stationary beamlines. One beamline
is designed to administer specialized

fixed-beam treatments, such as those
used to treat certain ocular conditions.
The second beamline will also have a
fixed beam for treating cancers that
require proton beams from a limited
number of directions, including brain,
head and neck, and prostate cancers.
Additionally, the center will contain
a separate room dedicated to research,
as well as clinic and office space and
treatment-planning stations. It is
anticipated that more than 3,000
patients with cancer will be treated
in the new center each year.
Powering the proton therapy treatments will be a high-energy synchrotron,
a compact particle accelerator that emits
proton beams of different energies. The
synchrotron and related proton beam
therapy equipment will be provided by
Hitachi. Other partners in the project
include the Houston-based financial
services firm Sanders Morris Harris, Inc.;
The Styles Company, a health-care
management and development firm; the
Houston Firefighters’ Relief and Retirement Fund; the Houston Police Officers’
Pension System; General Electric; Varian
Medical Systems; and IMPAC Medical
Systems.
“This creates a unique relationship
that partners academic medicine with
the private sector,” said Latinkic. While
M. D. Anderson will be fully responsible
for operating, staffing, and clinically
directing the center, the investors will
provide the necessary capital and
participate in the development of the
facility. According to Latinkic, the
center will also have a strong commitment to clinical research, as well as to
the advancement of proton therapy
research and development.
“We are going to develop collaborative investigations with a small number
of proton facilities around the world,”
said Dr. Cox. As part of the Proton
Therapy Cooperative Oncology Group,
M. D. Anderson will work with colleagues at Loma Linda University
Medical Center, Massachusetts General
Hospital, and other facilities around
the world to conduct clinical trials of
proton therapy for different tumor sites.
Much of the cancer research being
conducted today is focused on biological
approaches to treating cancer, including
gene therapy and molecular targeting.
Once these approaches are available
internationally, Dr. Cox hopes that the

Dr. James D. Cox, professor and head
of the Division of Radiation Oncology,
speaks at the groundbreaking ceremony
for the new Proton Therapy Center.
cooperative group can study them in
combination with proton therapy and
standard chemotherapy. Such combination therapies will be particularly
important for sites like the lung, which
is very sensitive to radiation and
difficult to treat with standard therapies.
Proton therapy will be used in conjunction with conventional radiation
therapy, chemotherapy, and surgery.
According to Dr. Cox, it will also have
a big impact in children, where the late
effects of conventional radiation
therapy can surface decades after initial

treatment and for whom the trend
of late has been to replace radiation
therapy with other treatment options.
Although the precision of proton
beam therapy has been known for
decades, applications were initially
limited to a few anatomic sites because
accelerators were not designed for
treating patients and because many
tumors could not be visualized with
sufficient precision. Beginning in the
late 1970s, imaging modalities, including
computed tomography, magnetic resonance imaging, and positron emission
tomography, greatly advanced the
diagnosis and visualization of cancerous
tumors, thus giving physicians the ability
to precisely map the location of tumors
and making proton therapy more
practical.
More than 33,000 patients with
cancer have already been treated with
proton radiation therapy, and this
number is expected to increase dramatically in the coming years as M. D.
Anderson’s Proton Therapy Center
becomes operational and the full impact
of this therapy and its applications
are realized. ●
FOR MORE INFORMATION, contact Dr. Cox
at (713) 792-3411 or Mitch Latinkic at
(713) 794-4720.

How Proton Therapy Works
• At the beginning of the process, which is measured in fractions of a second,
the proton begins its journey within an electric field. In the field, hydrogen
atoms are separated into electrons and protons.
• Protons are then sent through a vacuum tube into a linear accelerator or
preaccelerator, where their energy is boosted to seven million electron volts.
• Proton beams stay in the vacuum tube as they enter the synchrotron, where
they are accelerated, increasing their energy to a total of 70 to 250 million
electron volts, enough to place them at any depth within the patient’s body.
• After leaving the synchrotron, the protons move through a beam-transport
system made up of a series of magnets that shape, focus, and direct the proton
beam to the appropriate treatment room.
• Each treatment room has a guidance system to direct the beam that treats the
patient. This system will monitor the proton beam until it enters the patient
and position the beam to conform to the shape and size of the tumor, according to a plan designed by the physician.
• The beam delivery system, or nozzle, is the last device the protons travel
through before entering the patient’s body. The nozzle shapes and spreads out
the proton beam in three dimensions.
• The entire proton therapy facility is controlled by a network of computers
that are equipped with appropriate safety measures to ensure that each patient
receives the prescribed treatments and that the entire proton beam therapy
system operates safely and efficiently. ●
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